# Pizarra — PT-pseudo_033f1a8e1503 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_033f1a8e1503
Task: 1

Encounter: Urology - outpatient on 12 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 60-year-old male
  - PSA: 5.9 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.199 ng/mL²
  - PSA velocity: 1.83 ng/mL/yr
  - Prior PSA: 4.1 ng/mL
  - Prostate volume: 29.71 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.84285355 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Coronary artery disease, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypertension, Coronary artery disease, Benign prostatic hyperplasia
  - Current medication: amlodipine, aspirin 80 mg, atorvastatin, metoprolol, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 5.9 ng/mL. PI-RADS 5. PSAD 0.20. Prostate volume 30 mL. csPCa 0.84.

Vitals: weight 82 kg, height 184 cm, BMI 24.2, BP 113/77 mmHg, HR 77 bpm. Smoking: Ex-smoker (31 pack-yr, quit 2022).

Chief complaint: Routine monitoring after mpMRI completion and detection of an upward PSA trajectory.

History: A 60-year-old retired carpenter who has never married and currently resides with his partner has remained under routine observation since an initial PSA elevation was flagged in April 2022. He walks twenty minutes daily and ceased tobacco use completely in 2022, concluding a thirty-one pack-year smoking history. His pharmacological profile consists of amlodipine, metoprolol, aspirin 80 mg, atorvastatin, and tamsulosin, the latter addressing benign prostatic hyperplasia that yields minor bothersome symptoms (IPSS 7/35). Underlying hypertension and coronary artery disease remain stable. No prior biopsy history has been recorded. Recent outpatient visits covered audiological screening, pulmonary function tests for established COPD, and dermatological evaluation for actinic keratosis. A cholecystectomy performed during his forties represents his only surgical history. He reports no acute complaints or systemic symptoms beyond these managed chronic conditions.

Physical examination: DRE reveals a uniformly smooth prostatic contour, free of nodularity or asymmetrical firmness. Systemic assessment shows no acute abnormalities, with cardiovascular and pulmonary signs aligning with his established medical background.

Patient info: retired carpenter; Never married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 3 units / week; exercise Walking 20 min/day; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Dermatology — actinic keratosis check; Pulmonary function test — known COPD follow-up; Audiology — hearing test.
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.75 +/- 0.18   (95% CI 0.34-0.98)

Where the uncertainty comes from:
  - aleatoric  dA = 0.15  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.10  (few labelled cases resemble this one)
  - 5.6 effective neighbours out of 10; 4 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'supports': A +/- dA does not cross 0.5, but A +/- 1.96*dA does. There is a direction, not a conclusion. Measured accuracy in this tier: 0.67. Treat it as a weighted vote, not as a decision.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=0.0, psa=5.9, age=60.0, psad=0.199, dre_ord=0.0, vol=29.71, n_pmhx=3.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's PSA velocity (1.83 ng/mL/yr) or the specific findings from the mpMRI report (PI-RADS 5) beyond the score itself, nor the full context of the PSA history trend. It also missed the specific details from the laboratory panel and previous notes that might modify the interpretation of the high PSA/PI-RADS score.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests biopsy with a high probability (0.75), but the uncertainty is high (dA=0.15). A failure mode is the high csPCa predicted probability (0.84285355) combined with a normal DRE, which might suggest a lower need for immediate biopsy if the MRI findings are equivocal or if the PSA velocity is not aggressive enough to warrant immediate intervention. Another failure mode is the prior positive biopsy status being 'None', meaning the decision is purely based on current imaging/labs, which might be insufficient without the full MRI prose.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the prose suggests a high likelihood of clinically significant cancer despite the PI-RADS 5, it would increase the need for biopsy.
  <document> PSA history (trend) -> If the trend is highly aggressive (e.g., very steep rise), it would increase the need for biopsy.
  <document> laboratory results -> If the lab panel shows any markers (e.g., PSA density context) that contradict the PI-RADS/PSA score, it would modify the risk assessment.
  <document> previous GP / urology consultation notes -> If prior notes mention specific concerns or follow-up plans related to the PSA trajectory, it would contextualize the current decision.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line - that is an honest result.
  
  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_033f1a8e1503", "radiology_report": "Multiparametric MRI Prostate | Amsterdam UMC, AMC | 05 January 2025\nClinical workup prompted by a PSA reading of 5.9 ng/mL alongside malignant suspicion.\n\nFINDINGS:\nGlandular volume registers at 29.71 mL. T2 sequences highlight a discrete hypointense focus located posteriorly in the mid-gland left peripheral zone, spanning 12 x 9 x 10 mm. Diffusion-weighted imaging shows pronounced restriction, mirrored by dark ADC mapping. Post-contrast dynamics capture rapid, localized enhancement against adjacent tissue. Extraprostatic spread and seminal vesicle involvement are absent. Pelvic nodal basins appear normal.\n\nIMPRESSION:\nPI-RADS 5 lesion in the left peripheral zone.\nProstate volume 29.71 mL; PSAD 0.199 ng/mL/mL.\ncsPCa predicted probability 0.84285355."}
  
  **psa_trend**
  {"case_id": "PT-pseudo_033f1a8e1503", "psa_trend": [{"date": "Apr 2022", "val": 4.2}, {"date": "Sep 2023", "val": 3.4}, {"date": "Jan 2025", "val": 5.9}]}
  
  **lab_results**
  {"case_id": "PT-pseudo_033f1a8e1503", "laboratory_results": [{"name": "PSA", "val": "5.9 ng/mL", "date": "10 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "0.93 ng/mL", "date": "10 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "16%", "date": "10 Dec 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "14.2 g/dL", "date": "10 Dec 2024", "flag": ""}, {"name": "WBC", "val": "4.7 x10^9/L", "date": "10 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "270 x10^9/L", "date": "10 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "96 umol/L", "date": "10 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "10 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "12.6 nmol/L", "date": "10 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "61 U/L", "date": "10 Dec 2024", "flag": ""}, {"name": "LDH", "val": "138 U/L", "date": "10 Dec 2024", "flag": ""}, {"name": "HbA1c", "val": "5.9 %", "date": "10 Dec 2024", "flag": ""}]}
  
  **previous_notes**
  {"case_id": "PT-pseudo_033f1a8e1503", "previous_notes": [{"date": "18 Jan 2024", "author": "Dr. C. Peters (GP)", "text": "Laboratory results showed a PSA rise to 4.1 ng/mL in September 2023, following a baseline of 2.8 ng/mL in April 2022. Driven by this trend and mild urinary complaints, clinicians ordered an mpMRI and initiated a urology referral. Tamsulosin remained part of the regimen for symptom management."}]}

NOT RETRIEVED
  get_family_history: Not called because the retrieval economy suggests it is not necessary for this specific decision based on the other retrieved data.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  PI-RADS 5 lesion in the left peripheral zone
  PSA velocity of 1.83 ng/mL/yr (from trend data)
  csPCa predicted probability of 0.84285355
  
  AGAINST sampling this patient now:
  Normal DRE findings
  
WHERE THIS LEANS
  The retrieved evidence strongly supports sampling due to the high-risk MRI finding (PI-RADS 5), the concerning PSA velocity, and the high predicted cancer probability, which aligns with the statistical prior. The normal DRE is a mitigating factor but does not negate the high-risk imaging and biochemical trajectory.

[Sections actually revealed in this consultation: radiology_report, psa_trend, laboratory_results, previous_notes. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended due to the high-risk imaging finding of a PI-RADS 5 lesion in the left peripheral zone and a concerning PSA velocity of 1.83 ng/mL/yr. This is further supported by the high csPCa predicted probability of 0.84285355 and the PSA trend showing a significant rise from 4.2 ng/mL to 5.9 ng/mL. The normal DRE is a mitigating factor but does not override the high-risk imaging and biochemical trajectory, leading to a clear recommendation for sampling.

Variables that carried weight: age=noted, dre=noted, psa=decisive, vol=noted, psad=important, cspca=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, laboratory_results, previous_notes
